HAL : in2p3-00586373, version 1

DOI : 10.1016/j.bmcl.2011.03.034

Fiche détaillée

Récupérer au format BibTeX - EndNote - TEI - RefWorks -

Bioorganic & Medicinal Chemistry Letters / Bioorganic and Medicinal Chemistry Letters 21 (2011) 3088-3091

Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation

H.-J. Ryu, S.-H. Lee, S. Hwang, V. Breton1, J. H. Rhee, D. Kim

(2011)

The 3C-like protease (3CLpro) of severe acute respiratory syndrome associated coronavirus (SARS-CoV) is vital for SARS-CoV replication and is a promising drug target. Structure based virtual screening of 308 307 chemical compounds was performed using the computation tool Autodock 3.0.5 on a WISDOM Production Environment. The top 1468 ranked compounds with free binding energy ranging from -14.0 to -17.09 kcal mol-1 were selected to check the hydrogen bond interaction with amino acid residues in the active site of 3CLpro. Fifty-three compounds from 35 main groups were tested in an in vitro assay for inhibition of 3CLpro expressed by Escherichia coli. Seven of the 53 compounds were selected; their IC50 ranged from 38.57 ± 2.41 to 101.38 ± 3.27 muM. Two strong 3CLpro inhibitors were further identified as competitive inhibitors of 3CLpro with Ki values of 9.11 ± 1.6 and 9.93 ± 0.44 muM. Hydrophobic and hydrogen bond interactions of compound with amino acid residues in the active site of 3CLpro were also identified.

1 :	LPC-CLERMONT - Laboratoire de Physique Corpusculaire de Clermont-Ferrand

Thème(s)

:

Informatique/Bio-informatique Sciences du Vivant/Bio-Informatique, Biologie Systémique

Mot(s)-clé(s) : 3CL Protease – Severe acute respiratory syndrome – SARS – Coronavirus – FRET-based assays – Autodock – Virtual screening – Grid

in2p3-00586373, version 1

http://hal.in2p3.fr/in2p3-00586373

oai:hal.in2p3.fr:in2p3-00586373

Contributeur : Jeanine Pellet <>

Soumis le : Vendredi 15 Avril 2011, 16:12:29

Dernière modification le : Mercredi 23 Novembre 2011, 14:02:40